View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Gerresheimer Group
22 February 2022

Gerresheimer Enters Into Agreement with Major American Biotech to Develop an Innovative Pump for Rare Diseases

Gerresheimer has entered into an important agreement involving its Advanced Technologies division. An established US biotech company will rely on Gerresheimer’s innovative strength and engineering expertise for the development of a new pump to deliver a leading drug for the treatment of rare diseases via continuous parenteral administration.

“This agreement is another important milestone on our way to becoming a solution provider for leading and innovative medical devices.” said Dietmar Siemssen, CEO of Gerresheimer AG. “Our patented pump technology has already proven itself in use for Parkinson’s therapy and in future we expect it will also help to improve the quality of life of people with rare diseases. Our broad portfolio for the pharma and biotech industry makes it possible to develop the best solution together with our customers and implement it with a perfect fit.”

The pump for the continuous parenteral administration of the liquid drug will be specially adapted by Gerresheimer to the needs of patients with this rare disease. The sales and revenue model is divided into two phases. First, the American biotech will fund the development of the pump. After the market launch, Gerresheimer will sell the pump to the biotech and receive both a transfer price and royalty. The project is already making a positive contribution to earnings development from the start – clear evidence of the successful implementation of the growth strategy.

The exclusive agreement between Gerresheimer and the American biotech addresses the regions USA and Canada, with a right of first refusal granted to the partner to cover additional territories. Gerresheimer therefore plans to have a pump approved by the United States Food and Drug Administration in the future.

The innovative pump consists of two parts, one of which can be reused, thus increasing the sustainability of the solution. At its core is the already patented SenseCore technology.

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being....
Gerresheimer is one of the leading specialists for the production of high-quality glass and plastic products for the international pharmaceutical and healthcare industry.
During the Covid-19 pandemic, Gerresheimer is focusing on aspects including business continuity, customer demand, and supply chain. In 2019, we paved the way for profitable...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology